Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Candriam S.C.A.

Candriam S.C.A. lowered its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 109,327 shares of the specialty pharmaceutical company's stock after selling 32,562 shares during the quarter. Candriam S.C.A. owned approximately 0.20% of Supernus Pharmaceuticals worth $3,953,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of SUPN. Pacer Advisors Inc. grew its position in shares of Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company's stock valued at $54,655,000 after purchasing an additional 403,028 shares during the period. Geode Capital Management LLC grew its holdings in Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock valued at $46,218,000 after buying an additional 74,438 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after acquiring an additional 40,968 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 1.1% in the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company's stock worth $23,163,000 after acquiring an additional 7,833 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Supernus Pharmaceuticals by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company's stock worth $14,449,000 after acquiring an additional 27,134 shares during the last quarter.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SUPN. StockNews.com downgraded shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Down 2.0 %

Shares of Supernus Pharmaceuticals stock traded down $0.64 during trading hours on Wednesday, hitting $31.38. The company's stock had a trading volume of 1,339,444 shares, compared to its average volume of 553,513. The business has a fifty day moving average of $36.54 and a 200 day moving average of $35.25. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The company has a market capitalization of $1.75 billion, a PE ratio of 29.33 and a beta of 0.83.

Insider Buying and Selling

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.